Get started
Author

Rafael Aron Schmerling

Observed names: R. A. Schmerling, R. Schmerling, R.A. Schmerling, Rafael A Schmerling, Rafael A. Schmerling, Rafael SCHMERLING, Rafael Schmerling, Raphael Aron Schmerling
Observed institutions: Universidade de São Paulo, Universidad de Buenos Aires, Hospital Italiano de Buenos Aires, Instituto do Câncer do Estado de São Paulo, Hospital de São José, Beneficência Portuguesa de São Paulo, Instituto Nacional de Cancerología, Hospital Alemán, Hospital do Coração, Instituto Nacional de Câncer - INCA, Hospital Sírio-Libanês, Latin American Cooperative Oncology Group (LACOG)
ORCID: 0000-0001-7541-8899
Observed ORCID: 0000-0001-7541-8899
OpenAlex ID: A5040238402
Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors
2016 · Jéssica Ribeiro Gomes, Rafael A. Schmerling, et al. · Journal of Immunotherapy · 91
Cutaneous melanoma in Latin America: the need for more data
2011 · Rafael A Schmerling, Dora Loria, et al. · Revista Panamericana de Salud Pública · 48
PDF
Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors
2017 · Alberto Julius Alves Wainstein, Aknar Calabrich, et al. · Brazilian Journal of Oncology · 24
Consensus of the Brazilian Society of Infectious Diseases and Brazilian Society of Clinical Oncology on the management and treatment of Kaposi's sarcoma
2014 · Érico Arruda, Alexandre Andrade dos Anjos Jacome, et al. · The Brazilian Journal of Infectious Diseases · 21
Demographic, Clinical, and Pathologic Features of Patients With Cutaneous Melanoma: Final Analysis of the Brazilian Melanoma Group Database
2020 · Alberto Julius Alves Wainstein, João Pedreira Duprat Neto, et al. · JCO Global Oncology · 18
PDF
Burden of Disease, Early Diagnosis, and Treatment of Merkel Cell Carcinoma in Latin America
2018 · Rafael A. Schmerling, Jose G. Casas, et al. · Journal of Global Oncology · 14
Workflow in Clinical Trial Sites & Its Association with Near Miss Events for Data Quality: Ethnographic, Workflow & Systems Simulation
2012 · Elias Cesar Araujo de Carvalho, Adelia Portero Batilana, et al. · PLoS ONE · 13
PDF
Toxicity of checkpoint inhibitors.
2014 · Rafael Aron Schmerling · PubMed · 12
Gastrointestinal stromal tumor of the rectum treated with neoadjuvant Imatinib followed by transanal endoscopic microsurgery
2015 · Caio Sergio Rizkallah NAHAS, Sergio Carlos NAHAS, et al. · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · 11
PDF
Challenges and opportunities for sarcoma care and research in Latin America: a position paper from the LACOG sarcoma group
2024 · Roberto Carmagnani Pestana, Bruna Bianca Lopes David, et al. · The Lancet Regional Health - Americas · 10
Brazilian consensus on the diagnosis and treatment of extremities soft tissue sarcomas
2020 · Ranyell M. S. S. B. Spencer, Veridiana P. de Camargo, et al. · Journal of Surgical Oncology · 10
Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective
2023 · Pamela Salman, Andreia Cristina de Melo, et al. · Frontiers in Oncology · 6
PDF
Immune Manifestations with Checkpoint Inhibitors in a Single Brazilian Center: Experience and Literature Review
2020 · Rafael A Schmerling, Antonio C Buzaid, et al. · Future Science OA · 6
Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts’ recommendations
2020 · Rodrigo Ramella Munhoz, Federico Cayol, et al. · Cancer Immunology Immunotherapy · 6
Mutation profile in non-small cell lung cancer: Analysis of a Brazilian population.
2015 · Jessica Ribeiro Gomes, Marcus Paulo Fernandes Amarante, et al. · Journal of Clinical Oncology · 5
Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
2021 · A. A. Formozo, J. R. Gomes, et al. · Journal of Skin Cancer · 4
PDF
Abscopal Effect in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors (Anti-CTLA-4 and Anti-PD1): A Retrospective Analysis of a Single Institution
2016 · R.F. Carvalho, R. Ferrigno, et al. · International Journal of Radiation Oncology*Biology*Physics · 4
PDF
Ipilimumab for stage unresectable III/IV melanoma: Brazilian experience in an expanded access program.
2014 · Rafael Schmerling, Daniel Herchenhorn, et al. · Journal of Clinical Oncology · 3
Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America: A Report From the LACOG Sarcoma Group
2025 · Douglas Dias e Silva, Bruna Bianca Lopes David, et al. · JCO Global Oncology · 2
Sarcoma drug approvals in Latin America compared to the FDA and EMA: An analysis by the LACOG Sarcoma Group.
2024 · Roberto Carmagnani Pestana, Douglas Dias e Silva, et al. · Journal of Clinical Oncology · 2
PDF
Abstract LB-055: Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment
2017 · Milton Barros e Silva, Rafael Schmerling, et al. · Cancer Research · 2
PCN61 Melody Brazil – Resource Use and Associated Costs With Metastatic Melanoma in Brazilian Health Care System
2012 · S.D. Stefani, M.E. Nita, et al. · Value in Health · 2
High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy
2011 · Antonio Carlos Buzaid, Rafael Aron Schmerling, et al. · Melanoma Research · 2
41P Assessment of rare cancers and sarcoma policy in National Cancer Control Plans (NCCPs) from South American countries: A report from the LACOG Sarcoma Group
2024 · R. Carmagnani Pestana, D. Silva, et al. · ESMO Open · 1
PDF
1641P Bone and soft tissue sarcoma in Brazil: Estimating the epidemiological landscape via a computerized data-capture tool
2020 · R. Ramella Munhoz, R. Schmerling, et al. · Annals of Oncology · 1
PDF
Works count: 48
Citation count: 322
H-index: 10
I10-index: 11
Year
Topic
Type